Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
GANX · NASDAQ · Pharmaceutical Preparations
Gain Therapeutics (GANX) · oqro.io/stocks/GANX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.9994−0.0506 (−4.82%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−64.9% (−$1.85) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $2.85 on Nov 20, 2025 to $0.9994 on Nov 20, 2026 (−64.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Bethesda, Md.
Last 12 months
−64.9%
Market value
$44.5M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.89M shares sold short (8.7% of shares outstanding), +21.9% vs the previous count, 5.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No open-market purchase by an insider of Gain Therapeutics was filed in the last 90 days. The latest on record was on Aug 9, 2024.
Since 2021, Gain Therapeutics insiders reported 11 open-market purchases and 2 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2024.
No open-market sale by an insider of Gain Therapeutics (GANX) was filed with the SEC in the last 90 days.
No trade in Gain Therapeutics (GANX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”) and metabolic disorders through molecular chaperoning to stabilize misfolded proteins and increase their activity, as well as other diseases that can be targeted through protein inactivation or modulation, such as oncology. We use our computational target and drug discovery platform, Magellan™, to discover novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease.
And 18 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 26, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Mar 26, 2026, compared with the one filed Mar 27, 2025. Read the filing
On January 21, 2026, Andrew Schwartzberg filed a complaint (the “Complaint”) against the Company and Gene Mack in the United States District Court for the District of Delaware. The Complaint alleges that we and Mr. Mack failed to honor an alleged agreement to amend the exercise price of Mr. Schwartzberg’s outstanding warrants, which agreement the Complaint alleges was made to induce Mr. Schwartzberg’s further investment in the Company. Based on these allegations, the Complaint asserts claims of: (1) breach of contract against the Company; (2) fraudulent inducement against us and Mr.
Source: SEC EDGAR, Form 10-K filed Mar 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
No Schedule 13D or 13G filing on GANX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net cash
$11.4M
Debt $309K, cash $11.7M, at Sep 30, 2026
Net income, last 12 months
−$18M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Revenue and earnings history, 6 fiscal yearsEarnings dates and the stock's moves
Last results
Nov 10, 2026
Within the 30 days after it, until Dec 10, 2026
Next results, expected
Not announced
Purchases after results
82%
9 of 11 insider purchases since 2021 came within 30 days after a results announcement
From Gain Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Gain Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 62.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (9.4% on ATS, 53.5% with other brokers), above its 26-week average of 57.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: MS POOL (ATS-4) (19.0%), INSTINCT X (15.0%), INTELLIGENT CROSS LLC (11.1%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Insiders of Gain Therapeutics reported 11 open-market purchases and 2 sales since 2021; purchases in 3 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $201K5×5 trades | — |
| 2023 | — | $5.1K2×2 trades |
| 2022 | $24.4M5×5 trades | — |
| 2021 | $39K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in parkinson disease. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Top officer leaving
“Resignation of Principal Financial Officer On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of Gain Therapeutics, Inc.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
On the public record for Gain Therapeutics over the 12 months to Nov 21, 2026: 1 clinical trial.